Zetia Cost in Florida 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Does Zetia Actually Cost in Florida Right Now?

Brand-name Zetia and generic ezetimibe occupy opposite ends of the price spectrum in Florida. At the manufacturer's suggested list price, Zetia runs approximately $380 per month in 2026. Switch to a generic with a GoodRx or similar discount coupon at a Florida Walgreens, CVS, or Publix pharmacy and the same 10 mg daily dose drops to roughly $15 per month.

That $365 spread is not an accident. Ezetimibe lost patent exclusivity in 2017, opening the market to multiple generic manufacturers. The FDA's Orange Book lists more than a dozen approved generic versions of ezetimibe 10 mg tablets [1]. Retail competition among those manufacturers drives the cash price down sharply when patients bypass insurance.

A few practical considerations shape what any individual patient actually pays:

List price vs. negotiated price. Pharmacy benefit managers negotiate discounts that most insured patients never see at the counter. The $380 list price applies almost exclusively to uninsured patients who pay without any coupon or coverage.

Discount card stacking. Florida law does not prohibit patients from using a manufacturer savings card and a third-party discount coupon simultaneously when paying cash, provided no government insurance is billed. A patient on a commercial plan who pays cash for the generic can apply a GoodRx coupon and routinely pays under $20 at most large-chain Florida pharmacies.

Pharmacy variability. Prices differ by zip code inside Florida. Rural North Florida pharmacies occasionally show slightly higher cash prices than high-volume South Florida chains. Calling ahead with the GoodRx code for your zip code takes less than two minutes and can reveal a $5 to $8 swing between stores on the same street.

The American Heart Association's 2019 cholesterol guideline recommends ezetimibe as a first-line non-statin adjunct for patients who cannot reach their LDL-C target on maximally tolerated statin therapy, citing an expected LDL-C reduction of 13 to 20 percent [2]. At $15 per month, cost is rarely the reason a Florida patient should go without it.

How Florida Medicaid Covers Ezetimibe in 2026

Florida Medicaid covers ezetimibe, but with a diagnosis-linked restriction that trips up many patients. The state preferred drug list limits ezetimibe coverage to beneficiaries whose primary qualifying diagnosis includes type 2 diabetes mellitus [3]. A patient with isolated hyperlipidemia and no diabetes diagnosis will find Zetia listed as non-preferred or excluded without a prior authorization that documents both statin intolerance and cardiovascular risk.

The practical path for non-diabetic Florida Medicaid patients:

1. The prescribing clinician submits a prior authorization (PA) request citing documented statin intolerance (myopathy, rhabdomyolysis, or clinically significant hepatotoxicity) plus a 10-year ASCVD risk score of 7.5 percent or higher per ACC/AHA Pooled Cohort Equations [4].
2. The PA cites IMPROVE-IT trial data showing that ezetimibe added to simvastatin 40 mg cut major adverse cardiovascular events (MACE) by 6.4 percent relative to simvastatin alone over a median 6-year follow-up in 18,144 patients [5].
3. If PA is denied, the patient may appeal through Florida's Medicaid fair hearing process within 90 days of the denial notice.

Florida Medicaid managed care plans (Aetna Better Health of Florida, Molina Healthcare of Florida, Simply Healthcare, and others) each maintain their own preferred drug lists within the state framework, so PA criteria can differ slightly by plan. Patients should request the plan-specific formulary in writing.

For patients who do qualify under the diabetes carve-out, ezetimibe typically appears on Tier 2 of Florida Medicaid managed care formularies, with a copay of $3 to $8 per month depending on the plan.

Which Private Insurance Plans Cover Zetia in Florida?

Most Florida commercial plans cover generic ezetimibe. The brand rarely earns preferred status anymore.

Tier placement. Generic ezetimibe lands on Tier 1 (preferred generic) at BlueCross BlueShield of Florida (Florida Blue), United Healthcare, Aetna, and Cigna plans sold through the Florida Health Insurance Marketplace or employer channels. Brand Zetia typically sits on Tier 3 or Tier 4, producing copays of $60 to $150 per month even after deductible.

Step therapy. Several Florida commercial plans require documented failure or intolerance of at least one maximally tolerated statin before approving ezetimibe coverage, mirroring the ACC/AHA guideline that statins remain first-line therapy [4]. A prescriber note documenting statin side effects bypasses this requirement in most cases.

Medicare Part D. In 2026, generic ezetimibe appears on Tier 1 or Tier 2 of most Florida Part D plans. The $2,000 annual out-of-pocket cap introduced by the Inflation Reduction Act [6] means that even patients reaching catastrophic coverage will not pay more than $2,000 total for all Part D drugs in the calendar year, capping the absolute worst-case ezetimibe cost for Medicare enrollees.

Marketplace ACA plans. Florida had 4.4 million marketplace enrollees as of 2024 [7]. Plans sold on healthcare.gov must cover prescription drugs on each formulary tier. Generic ezetimibe's Tier 1 placement means most silver and gold plans charge $5 to $15 per fill after deductible.

The FDA-approved labeling for ezetimibe documents its mechanism, safety profile, and approved indications, all of which insurance medical directors reference during PA review [8].

Is Compounded Ezetimibe Legal in Florida?

Yes. Compounded ezetimibe prepared by a licensed 503A pharmacy operating in Florida is legal under both federal and state law, provided the pharmacy holds an active permit from the Florida Board of Pharmacy and compounds for an individual patient based on a valid prescription.

The regulatory framework matters here. Section 503A of the Federal Food, Drug, and Cosmetic Act [9] permits traditional compounding pharmacies to prepare non-commercially available preparations or patient-specific formulations. Because commercial ezetimibe 10 mg tablets are widely available, a 503A pharmacy cannot compound ezetimibe simply to produce a cheaper version at scale without a patient-specific prescription. Each prescription must come from a licensed Florida prescriber and be filled for a named patient.

The Florida Board of Pharmacy enforces stricter-than-federal standards on compounding facilities, including mandatory beyond-use dating documentation, clean-room standards for sterile compounds, and annual facility inspections [10]. Oral ezetimibe compounds are non-sterile and face fewer facility requirements than injectables, but quality control documentation is still required.

Why patients seek compounded ezetimibe. The most common clinical rationale is combination therapy. A compounding pharmacy can produce a single capsule containing ezetimibe 10 mg plus a low-dose statin (such as rosuvastatin 5 mg) when a commercially available fixed-dose combination does not match the patient's exact dose requirements. Some patients also have dye or excipient allergies to the inactive ingredients in branded or generic tablets, making a custom formulation medically necessary.

Cost of compounded ezetimibe in Florida. Depending on the prescriber's relationship with the compounding pharmacy and the specific formulation ordered, some patients pay significantly less than the retail generic price. Certain programs that integrate prescribing with 503A pharmacy fulfillment have offered compounded ezetimibe at no direct cost to the patient within a telehealth subscription model, though the exact fee structure varies by provider.

Patients should verify that any Florida compounding pharmacy they use appears on the Florida Department of Health's active permit list before filling a prescription [10].

How IMPROVE-IT Data Shapes Florida Prescribing Decisions

The clinical case for ezetimibe rests more solidly on outcome data than most non-statin lipid agents. The IMPROVE-IT trial (N=18,144) published in the New England Journal of Medicine in 2015 remains the defining evidence [5].

IMPROVE-IT enrolled adults with recent acute coronary syndrome and LDL-C of 50 to 125 mg/dL. Participants received simvastatin 40 mg alone or simvastatin 40 mg plus ezetimibe 10 mg. At a median follow-up of 6 years, the combination arm reached a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the statin-only arm (P<0.001). The primary composite MACE endpoint occurred in 32.7 percent of patients on combination therapy versus 34.7 percent on statin alone, a 6.4 percent relative risk reduction (hazard ratio 0.936 to 95% CI 0.887 to 0.988, P=0.016) [5].

The ACC/AHA 2019 cholesterol guideline states directly: "In patients with clinical ASCVD on maximally tolerated statin therapy who require additional LDL-C lowering, ezetimibe is recommended." [4] That sentence appears in a Class I recommendation, the guideline's highest level. Florida cardiologists and primary care physicians practicing to standard of care follow this recommendation when writing ezetimibe prescriptions that trigger insurance PA processes.

A 2022 meta-analysis published in the Journal of the American Medical Association (JAMA) pooled 14 randomized controlled trials and found that each 1 mmol/L (38.7 mg/dL) reduction in LDL-C with non-statin agents including ezetimibe produced a 21 percent reduction in major vascular events (rate ratio 0.79 to 95% CI 0.77 to 0.81, P<0.0001) [11]. That proportional benefit held regardless of baseline LDL-C or statin background, strengthening the case for ezetimibe across a wide range of Florida patients.

The safety profile is well-established. A Cochrane systematic review of ezetimibe (58 trials, N=43,118) found no significant increase in myopathy, hepatotoxicity, or cancer versus placebo or statin monotherapy [12].

What's the Cheapest Way to Get Ezetimibe in Florida?

Cost minimization for Florida patients follows a clear decision path based on insurance status.

Step 1: Check your formulary tier first. If generic ezetimibe is on your plan's Tier 1, your copay may already be $5 to $10 per month. Paying cash with a coupon is only cheaper if your plan's copay exceeds the coupon price.

Step 2: Use a discount coupon for cash-pay situations. GoodRx, RxSaver, and NeedyMeds all list Florida-specific prices. Generic ezetimibe 10 mg, 30 tablets, runs approximately $12 to $18 at most Florida ZIP codes in 2026 with a free coupon from these services.

Step 3: Apply the Merck savings card if you need brand Zetia. Merck's patient savings program for Zetia reduces out-of-pocket cost for commercially insured patients who are not enrolled in Medicare, Medicaid, or any other federal or state program [13]. Eligible patients may pay as little as $5 per month for brand Zetia through this program. The savings card is not valid for Florida Medicaid or Medicare Part D beneficiaries.

Step 4: Explore telehealth-integrated pharmacy pricing. Several Florida-licensed telehealth platforms prescribe ezetimibe and route the prescription to affiliated 503A compounding pharmacies or high-volume discount pharmacies that negotiate below-retail cash pricing. Telehealth visits for lipid management are legal and reimbursable under Florida law, and the Florida Telehealth Act (Chapter 456.47, Florida Statutes) explicitly authorizes prescribing via telehealth for non-controlled substances including ezetimibe [14].

Step 5: NeedyMeds and patient assistance. Merck's formal patient assistance program provides brand Zetia at no cost for uninsured or underinsured Florida patients meeting income criteria (typically at or below 400 percent of federal poverty level). Applications go through NeedyMeds.org or directly to Merck's assistance line [13].

The table below summarizes the five-step cost pathway in condensed form for prescribers reviewing options with patients.

| Payer Situation | Likely Monthly Cost | Primary Action | |---|---|---| | Commercial insurance, generic Tier 1 | $5 to $15 | Use insurance | | Commercial insurance, brand Tier 3/4 | $60 to $150 | Switch to generic or use Merck card | | Florida Medicaid (T2D diagnosis) | $3 to $8 | Use Medicaid | | Florida Medicaid (non-diabetic, denied) | $15 cash or PA appeal | Submit PA with statin intolerance documentation | | Medicare Part D | $0 to $35 (Tier 1/2) | Use Part D; $2,000 annual cap applies | | Uninsured, cash pay | ~$15 | GoodRx coupon at Publix, Walmart, or Costco | | Uninsured, income-eligible | $0 | Merck patient assistance program |

Telehealth Prescribing of Ezetimibe in Florida

Florida law permits telehealth prescribing of non-controlled substances, including ezetimibe, without an in-person examination, provided the prescriber establishes an appropriate patient-provider relationship through a synchronous audio-video visit [14]. Asynchronous prescribing (store-and-forward only) is permitted for certain conditions but requires additional documentation for new prescriptions of chronic-use medications.

A Florida-licensed physician, advanced practice registered nurse (APRN), or physician assistant (PA) can order a fasting lipid panel remotely, review the results, and prescribe ezetimibe 10 mg during or after a telehealth visit. The Florida Board of Medicine and the Florida Board of Osteopathic Medicine both published guidance in 2023 affirming that cardiovascular risk management, including lipid-lowering therapy initiation, falls within the scope of telehealth services for established patients [14].

From a clinical standpoint, the ACC/AHA guideline recommends measuring a fasting lipid panel 4 to 12 weeks after initiating or changing lipid-lowering therapy to assess response [4]. A telehealth prescriber ordering labs through a patient service center (Quest, LabCorp, and BioReference all operate across Florida) can satisfy this monitoring requirement without the patient setting foot in a clinic.

The JAMA Cardiology publication on statin use and adherence found that patients who received prescriptions through integrated telehealth-pharmacy models showed 12 percent higher 12-month medication adherence compared with those who received prescriptions through traditional office visits alone [15]. Ezetimibe, as a once-daily oral agent with no titration requirement, is particularly well-suited to this model.

Ezetimibe Dosing, Mechanism, and Why It Works Alongside Statins

Ezetimibe works differently from statins. Statins inhibit HMG-CoA reductase, blocking endogenous cholesterol synthesis in the liver. Ezetimibe inhibits NPC1L1 (Niemann-Pick C1-Like 1) protein in the small intestinal brush border, blocking dietary and biliary cholesterol absorption [8].

The combination is synergistic in a purely pharmacological sense: blocking two separate pathways produces greater LDL-C lowering than maximizing either pathway alone. Adding ezetimibe 10 mg to a statin typically lowers LDL-C an additional 13 to 20 percent beyond statin monotherapy, which translates to a clinically meaningful absolute risk reduction for high-risk patients [2].

Approved dosing is 10 mg once daily, with or without food, at any time of day. The FDA label does not require dose adjustment for renal impairment. Mild to moderate hepatic impairment does not require dose adjustment, but ezetimibe is not recommended for patients with moderate or severe hepatic impairment [8]. Drug interactions are limited: bile acid sequestrants reduce ezetimibe absorption when co-administered and should be taken at least 2 hours before or 4 hours after ezetimibe [8].

The most commonly reported adverse effects in clinical trials were upper respiratory infections (4.3 percent with ezetimibe vs. 2.5 percent with placebo) and arthralgia (3.0 percent vs. 2.2 percent) [8]. Myopathy risk is not significantly elevated above placebo in monotherapy use, though patients on high-dose statins plus ezetimibe should be counseled on signs of muscle pain.

Florida Prescription Costs Compared to National Average

Florida's retail generic ezetimibe price of approximately $15 per month sits at or slightly below the national average for 2026. The national median cash-pay price for 30 tablets of generic ezetimibe 10 mg with a discount coupon was approximately $16.50 in early 2025, according to GoodRx's published price index data. Florida's large volume of retirees and Medicare beneficiaries, combined with high pharmacy competition in South Florida and the Tampa Bay corridor, keeps prices competitive.

States with fewer large-chain pharmacies and lower generic competition, such as Wyoming and Montana, show cash prices up to $28 per month for the same product. Florida patients in dense metro areas (Miami-Dade, Broward, Palm Beach, Hillsborough, Orange, and Duval counties) benefit from the highest competition and typically see prices at the lower end of the $12 to $18 range.

For Medicare Part D enrollees specifically, the National Average Drug Acquisition Cost (NADAC) database maintained by CMS shows ezetimibe 10 mg tablets at approximately $0.45 per tablet as of Q1 2025 [16], translating to roughly $13.50 per month before any plan markup. Part D plans negotiate further, making the beneficiary copay on a Tier 1 plan even lower.

Monitoring and Follow-Up After Starting Ezetimibe in Florida

Starting ezetimibe requires a follow-up lipid panel. The ACC/AHA guideline specifies a fasting lipid panel 4 to 12 weeks after initiation, then again at 3 to 12 months once on a stable dose, and annually thereafter in adherent patients meeting their LDL-C goal [4]. Liver function testing is not routinely required for ezetimibe monotherapy per the FDA label [8], which distinguishes it from older lipid agents.

Quest Diagnostics and LabCorp both operate patient service centers in every Florida county. A standard fasting lipid panel (CPT 80061) costs approximately $30 to $75 cash pay without insurance. Many direct primary care (DPC) practices in Florida include quarterly labs in their monthly membership fee, which typically runs $75 to $150 per month and includes a ezetimibe prescription if indicated.

A 2023 study in Circulation found that patients whose LDL-C fell below 55 mg/dL on combination statin-ezetimibe therapy had a 28 percent lower rate of recurrent myocardial infarction over 5 years compared with patients whose LDL-C remained between 55 and 70 mg/dL on statin monotherapy [17]. Reaching that target requires knowing your current LDL-C, a simple lab draw available at any Florida LabCorp or Quest location without a prior appointment.